

1
2
3 **A 2SIR-VD Model for Optimizing Geographical COVID-19 Vaccine Distribution**
4 **in the Philippines**
5
6
7

8 Allan Paolo L. Almajose¹, Angus White², Chelsea Diego³, Red Lazaro³,
9 and Nicanor Austriaco, O.P.^{2,3,*}
10

11
12
13 *¹Department of Chemical Engineering, University of Philippines-Diliman,*
14 *Quezon City, Philippines.*

15
16 *²Department of Biology, Providence College,*
17 *Providence, Rhode Island, U.S.A.*
18

19 *³Department of Biological Sciences, University of Santo Tomas,*
20 *Manila, Philippines*
21

22
23
24 Running Title: A 2SIR-VD Model for Optimizing Vaccine Distribution
25 in the Philippines
26

27 Keywords: SIR model, vaccine distribution, COVID-19, Philippines
28
29
30
31
32

33 *Corresponding Author:

34 Rev. Nicanor Pier Giorgio Austriaco, O.P., Ph.D., S.Th.D.

35 Visiting Professor of Biological Sciences

36 University of Santo Tomas

37 naustriaco@ust.edu.ph

38

ABSTRACT

39

COVID-19 is a novel respiratory disease first identified in Wuhan, China, that is

40

caused by the novel coronavirus, SARS-CoV-2. It has triggered a global pandemic of

41

historic proportions. The government of the Philippines began its national vaccine drive

42

on March 1, 2021, with the goal of vaccinating seventy million of its citizens by the end

43

of the calendar year. To determine the optimum geographical distribution strategy in the

44

Philippines for the limited supply of vaccines that is currently available, we developed

45

and adapted a basic SIR model that allows us to understand the evolution of a pandemic

46

when public health authorities are vaccinating two susceptible populations within a

47

country with different vaccine rates. Our analysis with our 2SIR-VD model revealed that

48

prioritizing vaccine deployment to the National Capital Region (NCR) of the Philippines

49

minimized the number of COVID-19 cases in the country. We therefore recommend

50

deploying 90% of the available vaccine supply to the NCR to mitigate viral transmission

51

there. The remaining 10% would allow the rest of the archipelago to vaccinate all of their

52

senior citizens, thus shielding this vulnerable population against severe disease and death

53

from COVID-19.

54

INTRODUCTION

55

COVID-19 is a novel respiratory disease first identified in Wuhan, China, that is caused by the coronavirus, SARS-CoV-2 (Guan et al., 2020; Xie et al., 2020; Zhu et al., 2020). With widespread human-to-human transmission, the virus is highly contagious, and the COVID-19 pandemic is now of global concern (Burki, 2020; Paules et al., 2020).

59

On January 30, 2020, the Department of Health (DOH) of the Philippines reported its first case of COVID-19 in the country. The first case of local transmission was confirmed on March 7, 2020, with the first death due to local transmission reported on March 11, 2020. As of April 18, 2021, there have been 936,133 confirmed cases and 15,960 deaths from COVID-19 reported by the DOH throughout the archipelago (ncovtracker.doh.gov.ph).

65

The government of the Philippines began its national vaccine drive on March 1, 2021, with the goal of vaccinating seventy million of its citizens by the end of the calendar year (Inter-Agency Task Force for the Management of Emerging Infectious Disease, 2021). The initial plan proposed to distribute vaccines equally across the geographic regions of the country according to priority groups by the government following WHO guidelines to mitigate mortality and morbidity. However, it is not clear if this geographic strategy of equal distribution across the archipelago would optimize the distribution of the limited numbers of available vaccines.

72

73 In this paper, we develop a basic SIR model that includes compartments for those
74 who have been vaccinated (V) and those who have died (D) and adapt it to determine
75 the optimum strategy to geographically distribute the limited stockpile of COVID-19
76 vaccines among the different regions of the Philippines. Though there have been other
77 studies that have simulated the dynamics of a pandemic under different vaccine
78 deployment conditions (Liu and Xia, 2011; Araz et al., 2012; Yu et al., 2016; Acuña-
79 Zegarra et al., 2020; Goldenbogen et al., 2020; Yang et al., 2020; Cheng et al., 2021;
80 Martínez-Rodríguez et al., 2021; Sjödin et al., 2021), we opted for a simpler model that
81 would allow us to use the real time data published by the Department of Health of the
82 Philippines, with all of its limitations and shortcomings.

83 Using our 2SIR-VD model, we compared five geographical distribution strategies
84 to determine which one would most efficiently end the pandemic in the Philippines: 1)
85 equal distribution throughout the country; 2) priority distribution to the NCR; 3) priority
86 distribution to the “NCR Plus” bubble established by the Philippine government during
87 the 1Q of 2021; 4) priority distribution to the three major metropolitan areas of Metro
88 Manila, Metro Cebu, and Metro Davao; and 5) priority distribution to the NCR Plus,
89 Metro Cebu, and Metro Davao. Our analysis revealed that prioritizing vaccine deployment
90 to the NCR minimized the number of COVID-19 cases in the country. We therefore
91 recommend first deploying 90% of the available vaccine supply to the NCR to mitigate

92 viral transmission there. The remaining 10% would allow the rest of the archipelago to
93 vaccinate all of their senior citizens, thus shielding this vulnerable population against
94 severe disease and death from COVID-19.

95

96


MODELLING METHODS

97 Epidemic Modeling: A standard susceptible-infected-recovered (SIR) compartmental
98 model was modified to include vaccinated (V) and deceased (D) populations in order to
99 study the effects of alternative vaccination strategies on the evolution of a pandemic. In
100 deriving the compartmental diagram and models, the following assumptions were made:

- 101 1. Population rates for infection recovery and death are assumed to follow the
102 standard first order behavior with respect to the infected population;
- 103 2. Infection rates are controlled by a standard autocatalytic first-order behavior;
- 104 3. Vaccination rates are held as constant, that is, the number of vaccinations per unit
105 time is not dependent to the amount of currently susceptible to infection, or
106 vaccinated individuals;
- 107 4. Recovered individuals are no longer susceptible to reinfection; and
- 108 5. Vaccination is assumed to be 100% effective, that is, vaccinated individuals are no
109 longer susceptible to reinfection.

110 We are aware that these assumptions are idealizations that will prevent us from making
111 real time predictions for the length of a particular pandemic as vaccination rates are
112 varied. However, they will allow us to accomplish the principal goal of this analysis, which
113 is to compare the relative efficiencies of vaccination strategies that prioritize different
114 geographical regions in the Philippines.

115 It is common practice to express epidemic modelling assumptions in terms of a
116 compartmental model diagram. Diagram (1) shows the susceptible-infected-recovered-
117 vaccinated-deceased (SIR-VD) compartmental model diagram used to simulate the
118 behavior of COVID-19 cases in the Philippines.



119
120 (1)

121 Expressed mathematically, equations (1) to (5) are the system of differential equations
122 that describe the dynamic behavior of the infection.

123
$$\frac{d[S]}{dt} = -k_1 - k_2[S][I] \tag{1}$$

124
$$\frac{d[I]}{dt} = k_2 [S][I] - k_3 [I] - k_4 [I] \quad (2)$$

125
$$\frac{d[R]}{dt} = k_3 [I] \quad (3)$$

126
$$\frac{d[D]}{dt} = k_4 [I] \quad (4)$$

127
$$\frac{d[V]}{dt} = k_1 \quad (5)$$

128 Constants k_2 , k_3 , and k_4 describe the first-order infection, recovery, and death rate
129 coefficients, which are normally found via regression of available datasets. Of utmost
130 importance, however, is k_1 , as this is the coefficient that describes the vaccination rate of
131 the susceptible population. Varying the values of k_1 allows us to visualize the epidemic
132 as it changes while the susceptible population is being inoculated. As a representation,
133 assuming that the temporal dimension is in weeks, a dimensional analysis of equation (1)
134 will directly show that the units of k_1 is in number of persons at a given time;

135
$$\frac{\text{persons}}{\text{week}} = -\{k_1\} - \frac{1}{\text{persons} \cdot \text{week}} \cdot \text{persons} \cdot \text{persons} \quad (7)$$

136
$$\{k_1\} = \frac{\text{persons}}{\text{day}} \quad (8)$$

137 If population ratios are used instead of actual populations in the state variables of the
138 model, as will be done in this paper, the rate k_1 is simply the inverse of days:

139
$$\frac{1}{week} = -\{k_1\} - \frac{1}{1 \cdot week} \cdot \{1\} \cdot \{1\} \quad (9)$$


140
$$\{k_1\} = \frac{1}{week} \quad (10)$$

141 Should it be required to vaccinate a certain amount of susceptible individuals, S_V , the
142 value of k_1 is calculated by dividing S_V with the total population of the system, N_T :

143
$$k_1 = \frac{S_V}{N_T} \quad (11)$$

144 This SIR-VD model will allow us to understand how a pandemic evolves as a vaccination
145 drive advances in a particular population.

146 We have also adapted our SIR-VD model to understand the evolution of a
147 pandemic when public health authorities are vaccinating two susceptible populations with
148 different vaccine rates. For simplicity's sake, we assume that the infected individuals that
149 belong to the distinct populations are indistinguishable, that is, there is an ideal mixing
150 between the two infected populations. Diagram (2) graphically represents our two-
151 population 2SIR-VD model with the underlying assumption that the two infected
152 populations resulting from the susceptible individuals ideally mix.



153

154

(2)

155 The model is mathematically represented by equations (12) to (17):

156
$$\frac{d[S_1]}{dt} = -k_1 - k_3[S_1][I] \quad (12)$$

157
$$\frac{d[S_2]}{dt} = -k_2 - k_4[S_2][I] \quad (13)$$

158
$$\frac{d[I]}{dt} = k_3[S_1][I] + k_4[S_2][I] - k_5[I] - k_6[I] \quad (14)$$

159
$$\frac{d[R]}{dt} = k_5[I] \quad (15)$$

160
$$\frac{d[D]}{dt} = k_6[I] \quad (16)$$

161
$$\frac{d[V]}{dt} = k_1 + k_2 \quad (17)$$

162 For equations (12) to (17), k_1 describes the vaccination rate for S_1 and k_2 characterizes

163 the vaccination rate for S_2 . Constants k_3 to k_6 describe the S_1 infection rate, S_2 infection

164 rate, infection recovery rate and death rate.

165 Assuming that vaccination is limited to a certain amount k_{vac} , the following
166 equation must hold true:

$$167 \quad k_{vac} = k_1 + k_2 \quad (18)$$

168 An important ramification of (18) is that the vaccinations may be weighted among the
169 two susceptible populations. This allows us to study the progress of the epidemic as two
170 populations are vaccinated with different rates. In this study, S_1 will be designated as the
171 target susceptible individuals, S_2 will be assigned as the remainder of the total population
172 of susceptible individuals. For example, in one of the scenarios we analyze in this paper,
173 the population of Filipinos living in the National Capital Region (NCR) of the Philippines
174 is designated S_1 , while the rest of the Filipino population living outside the NCR would
175 be S_2 . In this way, k_1 is set as the rate of vaccination of the target susceptible individuals
176 which are normally less than the remainder of the total susceptible individuals. Should S_1
177 evaluate to zero, the vaccination rate will be transferred to the remainder of the total
178 susceptible individuals S_2 , that is:

$$179 \quad \text{if } S_1 \leq 0; \quad \begin{cases} k_1 = 0 \\ k_2 = k_{vac} \end{cases} \quad (17)$$

180 In principle, this 2SIR-VD model can also be used to evaluate the effect of vaccinating
181 any two distinct populations within a certain geographical area that differ by age, by
182 gender, or by residential location.

183

184 Data Gathering and Numerical Solution Methods: COVID-19 data was extracted
185 manually from the Philippine Department of Health's (DOH) nCoV-2019 Tracker
186 (ncovtracker.doh.gov.ph). The data used for this paper was preprocessed by evaluating
187 the number of active cases, the cumulative recoveries, and cumulative deaths due to the
188 epidemic per week as provided by the tracker. We chose to include epidemic information
189 on a weekly basis to reduce the amount of data scatter and errors that we had observed
190 because of delayed reporting of information by the DOH. Further, we discovered that this
191 allowed us to properly account for the weekly recovery rates announced by the DOH.

192 In training the model, the weekly information between February 18, 2021 and
193 March 31, 2021 was used. Given the disproportionate impact of the second surge on the
194 overall numbers of the pandemic in the Philippines, we decided to limit our model to the
195 2021 first quarter surge of COVID-19 cases.

196 The numerical population values used in the study were taken from the Philippine
197 Statistics Authority's (PSA) QuickStat spreadsheets. A logistic model was used to predict

198 the 2021 population values using the available 2000, 2007, 2010, and 2015 population
 199 information. The population numbers are displayed in Table 1.

200 In order to determine the rate for the systems of differential equations described
 201 by the 2SIR-VD model, numerical integration of the differential equations had to be
 202 applied with initial trial values for k_2 to k_4 using the standard SIR-V model, and trial
 203 values for k_3 to k_6 using the 2SIR-VD model. The fourth-order Runge-Kutta technique
 204 was used in integrating the systems of differential equations implemented in Microsoft
 205 Excel, with small temporal steps undertaken to assure numerical stability. Errors were
 206 calculated by evaluating the population ratio difference between those predicted by the
 207 mathematical models and the data. The normalized sum of squares of residuals is used as
 208 the objective function to train the rate constant data:

$$\begin{aligned}
 \varepsilon = & \sum_{i=1}^{n_{DATA}} \left(\frac{S_{DATA,i} - S_{MODEL,i}}{\sigma_{S_{MODEL}}} \right)^2 + \sum_{i=1}^{n_{DATA}} \left(\frac{I_{DATA,i} - I_{MODEL,i}}{\sigma_{I_{MODEL}}} \right)^2 \\
 & + \sum_{i=1}^{n_{DATA}} \left(\frac{R_{DATA,i} - R_{MODEL,i}}{\sigma_{R_{MODEL}}} \right)^2 + \sum_{i=1}^{n_{DATA}} \left(\frac{D_{DATA,i} - D_{MODEL,i}}{\sigma_{D_{MODEL}}} \right)^2
 \end{aligned} \tag{17}$$

$$\begin{aligned}
 \varepsilon = & \sum_{i=1}^{n_{DATA}} \left(\frac{S_{1DATA,i} - S_{1MODEL,i}}{\sigma_{S_{1MODEL}}} \right)^2 + \sum_{i=1}^{n_{DATA}} \left(\frac{S_{2DATA,i} - S_{2MODEL,i}}{\sigma_{S_{2MODEL}}} \right)^2 + \sum_{i=1}^{n_{DATA}} \left(\frac{I_{DATA,i} - I_{MODEL,i}}{\sigma_{I_{MODEL}}} \right)^2 \\
 & + \sum_{i=1}^{n_{DATA}} \left(\frac{R_{DATA,i} - R_{MODEL,i}}{\sigma_{R_{MODEL}}} \right)^2 + \sum_{i=1}^{n_{DATA}} \left(\frac{D_{DATA,i} - D_{MODEL,i}}{\sigma_{D_{MODEL}}} \right)^2
 \end{aligned} \tag{18}$$

211 Equation (17) is applicable to the original SIR-VD model, while equation (18) was used
212 to train the rate coefficients of the 2SIR-VD model.

213 To determine the final and converged rate constant values, the in-house Microsoft
214 Excel Solver add-in's Nonlinear Generalized Reduced Gradient method was used. Non-
215 negativity constraints are assigned to the rate constants to facilitate convergence and
216 correct behavior of the model. Further, central finite formulations have been used to
217 evaluate the numerical derivative for the gradient, with the method converging at the
218 error tolerance of 1×10^{-8} .

219 An excel file that incorporates the 2SIR-VD model described here has been archived
220 at GitHub with the following DOI: 10.5281/zenodo.475642.

221

222 RESULTS & DISCUSSION

223 To compare potential COVID-19 vaccination strategies that prioritized different
224 geographic populations in the Philippines, we developed a 2SIR-VD model that would
225 allow us to simulate the spread of the pandemic while two different populations were
226 being vaccinated at different rates. Because of the shortcomings and limitations of the
227 available COVID-19 pandemic data provided by the Department of Health of the
228 Philippines, we decided to construct a basic compartmental model with the minimum

229 number of compartments that would allow us to test different vaccine deployment
230 strategies that prioritized different geographical regions of the country.

231 To evaluate the quality and forecasting potential of our 2SIR-VD model, we began
232 by comparing simulations of the pandemic at the beginning of the second surge of COVID-
233 19 in the Philippines to the data made available by the Department of Health (DOH). As
234 shown in Figure 1, our model accurately simulated the growth of the pandemic in the
235 country as well as in the National Capital Region (NCR). Since the second surge of the
236 pandemic was concentrated in the NCR, it is not surprising that the country-wide curve
237 and the capital-only curve were similar in form and shape.

238 Once we had determined that our model accurately simulated the growth of the
239 pandemic during the second surge of COVID-19 in the Philippines, we used it to
240 interrogate the impact of vaccinations on the dynamics of the pandemic. We chose to
241 model the impact of a single-dose vaccine that conferred full protection against COVID-
242 19. This is clearly an idealized scenario for the COVID-19 pandemic where most of the
243 available vaccines require two doses separated by different periods of time, with different
244 reported efficacy rates, but we believe that the model is sufficient to give public policy
245 makers a sense of the impact of vaccination on the dynamics of the pandemic.

246 As shown in Figure 2, a simulation of the spread of the pandemic in the Philippines
247 after the second surge of COVID-19 without any nonpharmaceutical interventions (NPI)

248 like masking, social distancing, or lockdowns in place revealed that the surge would have
249 peaked when the number of active cases of COVID-19 representing the individuals in the
250 infected (I) compartment reached 11,345K. In contrast, the deployment of COVID-19
251 vaccinations at weekly rates of 500K, 1M, 2M, and 3M, would lower the peak to 73%,
252 49%, 18%, and 8% of its no vaccination value. Once again, we acknowledge that this is
253 an idealized model that assumes equal distribution of the vaccination throughout the
254 Philippines without any nonpharmaceutical interventions to halt the spread of the
255 infection. The simulation is an attempt to discern the relative impact of vaccinations on
256 the total number of COVID-19 cases in the country. The model predicts that the
257 mathematical relationship between the weekly rate of vaccination and the decrease in
258 COVID-19 cases is not linear. Rather, as vaccination rates rise, the comparable fall in
259 total number of COVID-19 cases decreases.

260 We then turned to the primary question of interest for this study by comparing
261 five vaccine deployment strategies that prioritize different geographical regions in the
262 Philippines. As a baseline, we simulated a whole country rollout where vaccines would be
263 equally distributed in the archipelago at a rate of 1M vaccinations per week. We then
264 explored the effects of rolling out the vaccines at a rate of 1M per week in the NCR first
265 (NCR), in Metro Manila, Metro Cebu, and Metro Davao first (3M), in the NCR Plus first
266 (NCR+), in the NCR Plus, Metro Cebu, and Metro Davao first (3M+). Metro Manila,

267 Metro Cebu, and Metro Davao are the three primary metropolitan regions of the
268 Philippines. The NCR Plus is a geographical region encompassing the NCR and the
269 adjacent provinces of Bulacan, Cavite, Laguna, and Rizal. This geographic “bubble” was
270 placed under the highest level of quarantine to contain the second surge of COVID-19 in
271 the capital region of the country. Note that our model is designed to transfer all the
272 remaining vaccines to the rest of the country once the prioritized region has been fully
273 vaccinated.

274 As shown in Figure 4, our simulation predicts that prioritizing the vaccine rollout
275 in the NCR where all the vaccines would be sent to the capital would dramatically
276 decrease the total number of COVID-19 cases in our idealized pandemic in the Philippines.
277 By prioritizing the NCR, the national vaccine strategy would lead to a 91% decrease in
278 the expected number of COVID-19 cases as compared to the whole country first scenario.
279 This NCR first scenario (91% decrease in total cases) is better than either a Metro Manila,
280 Metro Cebu and Metro Davao first scenario (87% decrease) or an NCR Plus first scenario
281 (81% decrease). Therefore, our simulation suggests that the national vaccine strategy
282 should target herd immunity in the NCR before inoculating the rest of the country in
283 order to most efficiently halt the pandemic in the Philippines.

284 Finally, we wanted to explore the effect of varying the ratio of vaccines deployed
285 to the NCR to vaccines sent to the rest of the Philippines. Numbers from the National

286 Task Force for COVID-19 from May 11, 2021, revealed that the current vaccine
287 deployment strategy of the national government distributes 40% of the national vaccine
288 supply to the NCR (2,495,970 doses to the NCR out of 6,408,640 total doses distributed).

289 As shown in Figure 5, our simulations reveal that increasing the percentage of
290 vaccines deployed to the NCR from 40% to 100% would lower the number of total COVID-
291 19 cases expected from the current strategy by 90%. However, we do not recommend
292 committing the entire vaccine supply to the NCR since this strategy does not acknowledge
293 that different segments of the population are at different risk for severe COVID-19 and
294 death. Rather, we propose that the national government commit 90% of the vaccine
295 supply to the NCR. The remaining 10% would be used to inoculate the medical frontliners
296 and senior citizens who are most at risk throughout the country. Senior citizens (60 years
297 old and above) make up about 9% of the total population of Filipinos according to
298 published statistics (<https://www.populationpyramid.net/philippines/>). Our model
299 revealed that deploying 90% rather than 100% of the vaccine supply to the NCR would
300 still decrease the predicted COVID-19 case load from the current strategy by 65%.
301 However, we would expect this strategy to decrease the total mortality rate since those
302 most at risk throughout the archipelago would still be inoculated first.

303 Our study is limited by the simplicity of our 2SIR-VD model, which does not take
304 into account the ever-changing non-pharmaceutical interventions that have been and are

305 being implemented in the Philippines to mitigate the COVID-19 pandemic. However, its
306 simplicity is also a strength because it allows us to account for the limitations and
307 shortcomings of the epidemic data provided by the Department of Health of the
308 Philippines. An earlier SIR model developed by one of us to model the pandemic in the
309 NCR (Egolf and Austriaco, 2020) was hampered by these shortcomings including
310 changing definitions of what constituted a patient who had recovered from COVID-19,
311 and inconsistent reporting schedules.


312 In sum, we have developed a 2SIR-VD model to determine if geographical
313 prioritization of the national COVID-19 vaccine supply in the Philippines would have a
314 significant impact on the dynamics of the pandemic. Our simulations reveal that
315 prioritizing vaccine deployment to the National Capital Region (NCR) would significantly
316 decrease the total case load of COVID-19 in the country. We therefore recommend
317 deploying 90% of the available vaccine supply to the NCR to first achieve herd immunity
318 there. The remaining 10% would allow the rest of the archipelago to vaccinate all of their
319 senior citizens, thus shielding this vulnerable population against severe disease and death
320 from COVID-19.

REFERENCES


- 321
- 322 ACUÑA-ZEGARRA MA, S DÍAZ-INFANTE, D BACA-CARRASCO & DO LICEAGA
- 323 [online]. 2020. COVID-19 optimal vaccination policies: a modeling study on efficacy,
- 324 natural and vaccine-induced immunity responses. medRxiv: 2020.11.19.20235176
- 325 Retrieved from
- 326 <http://medrxiv.org/content/early/2020/11/20/2020.11.19.20235176.abstract> on
- 327 January 1, 2020.
- 328 ARAZ OM, A GALVANI & LA MEYERS. 2012. Geographic prioritization of
- 329 distributing pandemic influenza vaccines. *Health Care Management Science* 15(3):
- 330 175–187 September 1, 2012. Springer Science and Business Media, LLC.
- 331 BURKI T. 2020. Outbreak of coronavirus disease 2019. *Lancet Infect Dis* 20: 292–293
- 332 2020.
- 333 CHENG S, R ARCUCCI, CC PAIN & Y-K GUO [online]. 2021. Optimal vaccination
- 334 strategies for COVID-19 based on dynamical social networks with real-time
- 335 updating. medRxiv: 2021.03.11.21253356 Retrieved from
- 336 <http://medrxiv.org/content/early/2021/03/12/2021.03.11.21253356.abstract> on
- 337 January 1, 2021.
- 338 EGWOLF B & N AUSTRIACO. 2020. Mobility-guided Modeling of the COVID-19
- 339 Pandemic in Metro Manila. *Philippine Journal of Science* 149(3): 857–868 2020.

- 340 GOLDENBOGEN B, SO ADLER, O BODEIT, JAH WODKE, X ESCALERA-
341 FANJUL, A KORMAN, et al. [online]. 2020. Optimality in COVID-19 vaccination
342 strategies determined by heterogeneity in human-human interaction networks.
343 medRxiv: 2020.12.16.20248301 Retrieved from
344 <http://medrxiv.org/content/early/2020/12/18/2020.12.16.20248301.abstract> on
345 January 1, 2020.
- 346 GUAN WJ, ZY NI, Y HU, WH LIANG, CQ OU, JX HE, et al. 2020. Clinical
347 Characteristics of Coronavirus Disease 2019 in China. *The New England journal of*
348 *medicine* 382(18): 1708–1720 April 30, 2020. NLM (Medline).
- 349 INTER-AGENCY TASK FORCE FOR THE MANAGEMENT OF EMERGING
350 INFECTIOUS DISSEASE [online]. 2021. The Philippine National COVID-19
351 Vaccination Deployment Plan | Department of Health website.
- 352 LIU J & S XIA. 2011. Toward effective vaccine deployment: A systematic study. Pp.
353 1153–1164, in: *Journal of Medical Systems*.
- 354 MARTÍNEZ-RODRÍGUEZ D, G GONZALEZ-PARRA & R-J VILLANUEVA-MICÓ
355 [online]. 2021. Analysis of key factors of a SARS-CoV-2 vaccination program: A
356 mathematical modeling approach. medRxiv: 2021.02.19.21252095 Retrieved from
357 <http://medrxiv.org/content/early/2021/02/23/2021.02.19.21252095.abstract> on
358 January 1, 2021.

- 359 PAULES C, H MARSTON & A FAUCI. 2020. Coronavirus infections-more than just
360 the common cold. JAMA 323: 707 2020.
- 361 SJÖDIN H, J ROCKLÖV & T BRITTON [online]. 2021. Evaluating and optimizing
362 COVID-19 vaccination policies: a case study of Sweden. medRxiv:
363 2021.04.07.21255026 Retrieved from
364 <http://medrxiv.org/content/early/2021/04/09/2021.04.07.21255026.abstract> on
365 January 1, 2021.
- 366 XIE J, Z TONG, X GUAN, B DU & H QIU. 2020. Clinical Characteristics of Patients
367 Who Died of Coronavirus Disease 2019 in China. JAMA network open 3(4):
368 e205619 2020.
- 369 YANG Y, Q LU, M LIU, Y WANG, A ZHANG, N JALALI, et al. 2020.
370 Epidemiological and clinical features of the 2019 novel coronavirus outbreak in
371 China. medRxiv: 2020.02.10.20021675 2020. Cold Spring Harbor Laboratory Press.
- 372 YU Z, J LIU, X WANG, X ZHU, D WANG & G HAN [online]. 2016. Efficient vaccine
373 distribution based on a hybrid compartmental model. PLoS ONE 11(5) Retrieved
374 from <https://pubmed.ncbi.nlm.nih.gov/27233015/> on May 1, 2016. Public Library
375 of Science.
- 376 ZHU N, D ZHANG, W WANG & et AL. 2020. A novel coronavirus from patients with
377 pneumonia in China, 2019. N Engl J Med 382: 727–733 2020.



379 Figure 1: Simulations of the Second Surge of COVID-19 in the Philippines Compared
380 to Real-time Data. Forecasted estimates of weekly new cases of COVID-19 for the
381 Philippines and the National Capital Region compared to the real-time data provided by
382 the Department of Health
383



384

385 **Figure 2: Idealized Simulation of the Impact of Vaccination on the COVID-19**


386 **Pandemic in the Philippines.** Forecasted dynamics for the spread of the pandemic in the

387 Philippines after the second surge of COVID-19 without any nonpharmaceutical


388 interventions (NPI) like masking or social distancing in place. We modeled the impact of

389 varying the rates of vaccination from 500K to 3M per week, equally distributed throughout

390 the country.



391
 392 **Figure 3: Idealized Simulation of the Impact of 1M/Week Vaccination Rollout on the**
 393 **COVID-19 Pandemic in the Philippines Prioritizing Different Regions in the Country.**
 394 Forecasted dynamics for the spread of the pandemic in the Philippines after the second
 395 surge of COVID-19 without any nonpharmaceutical interventions (NPI) like masking or
 396 social distancing in place. We modeled the impact of prioritizing different regions of the
 397 country by deploying 1M vaccines per week to a particular region first before distributing
 398 them to the rest of the country.



399

400 **Figure 4: Idealized Simulation of the Impact of Prioritizing Vaccination in the NCR**
 401 **on the COVID-19 Pandemic in the Philippines.** Forecasted dynamics for the spread of
 402 the pandemic in the Philippines after the second surge of COVID-19 without any
 403 nonpharmaceutical interventions (NPI) like masking or social distancing in place. We
 404 modeled the impact of varying the proportion of 1M vaccines deployed per week in the
 405 NCR. The remaining vaccines would be deployed to the rest of the country.

Geographical Region	Estimated Population (2021)
Bulacan	3,555,314
Laguna	3,425,983
Rizal	3,245,892
Cavite	4,227,720
Metro Cebu	3,430,503
Metro Davao	1,872,075
NCR	13,802,153
Philippines	112,868,636

Table 1: Population Values used for our Model Simulations. The numerical population values used in the study were taken from the Philippine Statistics Authority's (PSA) QuickStat spreadsheets. A logistic model was used to predict the 2021 population values using the available 2000, 2007, 2010, and 2015 population information.